GlycoGenesys, Inc. to Present at Bio-Europe 2004 10th International Pharmaceutical and Biotechnology Partnering Conference

Business Wire, Nov 8, 2004

BOSTON -- GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company developing novel drug candidates based on glycobiology, today announced that Frederick E. Pierce, II, Vice President of Business Development will make a corporate presentation at Bio-Europe's 10th International Pharmaceutical Partnering Conference on Tuesday, November 9th, 2004 at 10:15 a.m. Eastern Standard Time. The conference, sponsored by several of the world's largest pharmaceutical and biotechnology companies, is being held in Cologne, Germany on November 8th-10th, 2004.

GlycoGenesys, Inc.

GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials at low dose levels for both colorectal and pancreatic cancers, stable disease and partial response documented. The Company is currently conducting a Phase I dose escalation trial to evaluate higher dose levels of GCS-100LE, a low ethanol formulation of GCS-100, at Sharp Clinical Oncology Research in San Diego, California. Further studies of GCS-100LE are planned for the first and second quarter of 2005. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.

Safe Harbor Statement

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including, but not limited to, risks of product development (such as failure to demonstrate efficacy or safety), risk related to FDA and other regulatory procedures, market acceptance risks, the impact of competitive products and pricing, the results of current and future licensing, joint ventures and other collaborative relationships, the results of financing efforts, developments regarding intellectual property rights and litigation, and other risks identified in the Company's Securities and Exchange Commission filings. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.